222 related articles for article (PubMed ID: 22902197)
1. Olvanil acts on transient receptor potential vanilloid channel 1 and cannabinoid receptors to modulate neuronal transmission in the trigeminovascular system.
Hoffmann J; Supronsinchai W; Andreou AP; Summ O; Akerman S; Goadsby PJ
Pain; 2012 Nov; 153(11):2226-2232. PubMed ID: 22902197
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.
Akerman S; Holland PR; Goadsby PJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):64-71. PubMed ID: 17018694
[TBL] [Abstract][Full Text] [Related]
3. Endovanilloids are potential activators of the trigeminovascular nocisensor complex.
Dux M; Deák É; Tassi N; Sántha P; Jancsó G
J Headache Pain; 2016; 17():53. PubMed ID: 27189587
[TBL] [Abstract][Full Text] [Related]
4. Signaling mechanisms of down-regulation of voltage-activated Ca2+ channels by transient receptor potential vanilloid type 1 stimulation with olvanil in primary sensory neurons.
Wu ZZ; Chen SR; Pan HL
Neuroscience; 2006 Aug; 141(1):407-19. PubMed ID: 16678970
[TBL] [Abstract][Full Text] [Related]
5. Anti-nociceptive and desensitizing effects of olvanil on capsaicin-induced thermal hyperalgesia in the rat.
Alsalem M; Millns P; Altarifi A; El-Salem K; Chapman V; Kendall DA
BMC Pharmacol Toxicol; 2016 Jul; 17(1):31. PubMed ID: 27439609
[TBL] [Abstract][Full Text] [Related]
6. Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.
Chakraborty S; Elvezio V; Kaczocha M; Rebecchi M; Puopolo M
J Physiol; 2017 Apr; 595(8):2639-2660. PubMed ID: 28094445
[TBL] [Abstract][Full Text] [Related]
7. Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptor-mediated endocannabinoid retrograde disinhibition.
Liao HT; Lee HJ; Ho YC; Chiou LC
Br J Pharmacol; 2011 May; 163(2):330-45. PubMed ID: 21232043
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors.
Hayase T
BMC Pharmacol; 2011 Jul; 11():6. PubMed ID: 21767384
[TBL] [Abstract][Full Text] [Related]
9. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.
Price TJ; Patwardhan A; Akopian AN; Hargreaves KM; Flores CM
Br J Pharmacol; 2004 Apr; 141(7):1118-30. PubMed ID: 15006899
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin.
Engel MA; Izydorczyk I; Mueller-Tribbensee SM; Becker C; Neurath MF; Reeh PW
Neuropeptides; 2011 Jun; 45(3):229-37. PubMed ID: 21514666
[TBL] [Abstract][Full Text] [Related]
11. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871
[TBL] [Abstract][Full Text] [Related]
12. Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential.
Appendino G; De Petrocellis L; Trevisani M; Minassi A; Daddario N; Moriello AS; Gazzieri D; Ligresti A; Campi B; Fontana G; Pinna C; Geppetti P; Di Marzo V
J Pharmacol Exp Ther; 2005 Feb; 312(2):561-70. PubMed ID: 15356216
[TBL] [Abstract][Full Text] [Related]
13. Sumatriptan inhibits TRPV1 channels in trigeminal neurons.
Evans MS; Cheng X; Jeffry JA; Disney KE; Premkumar LS
Headache; 2012 May; 52(5):773-84. PubMed ID: 22289052
[TBL] [Abstract][Full Text] [Related]
14. Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.
Ursu D; Knopp K; Beattie RE; Liu B; Sher E
Eur J Pharmacol; 2010 Sep; 641(2-3):114-22. PubMed ID: 20576527
[TBL] [Abstract][Full Text] [Related]
15. Opposing roles for cannabinoid receptor type-1 (CB₁) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats.
Casarotto PC; Terzian AL; Aguiar DC; Zangrossi H; Guimarães FS; Wotjak CT; Moreira FA
Neuropsychopharmacology; 2012 Jan; 37(2):478-86. PubMed ID: 21937980
[TBL] [Abstract][Full Text] [Related]
16. Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.
Fioravanti B; De Felice M; Stucky CL; Medler KA; Luo MC; Gardell LR; Ibrahim M; Malan TP; Yamamura HI; Ossipov MH; King T; Lai J; Porreca F; Vanderah TW
J Neurosci; 2008 Nov; 28(45):11593-602. PubMed ID: 18987195
[TBL] [Abstract][Full Text] [Related]
17. GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus.
Andreou AP; Shields KG; Goadsby PJ
Neurobiol Dis; 2010 Feb; 37(2):314-23. PubMed ID: 19837163
[TBL] [Abstract][Full Text] [Related]
18. TRPV1 in migraine pathophysiology.
Meents JE; Neeb L; Reuter U
Trends Mol Med; 2010 Apr; 16(4):153-9. PubMed ID: 20347391
[TBL] [Abstract][Full Text] [Related]
19. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Zhang X; Strassman AM; Novack V; Brin MF; Burstein R
Cephalalgia; 2016 Aug; 36(9):875-86. PubMed ID: 26984967
[TBL] [Abstract][Full Text] [Related]
20. Two TRPV1 receptor antagonists are effective in two different experimental models of migraine.
Meents JE; Hoffmann J; Chaplan SR; Neeb L; Schuh-Hofer S; Wickenden A; Reuter U
J Headache Pain; 2015; 16():57. PubMed ID: 26109436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
